Home › Calculator › ZVRA Dividend Calculator 2026
ZVRA Dividend DRIP Calculator 2026
16.13% YieldHealthcareZevra Therapeutics, Inc. · NASDAQ
Price: $12.40 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ZVRA pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ZVRA snowball 📈
$10,000 in ZVRA → $772.22M in 10 years · $62,759,692.22/month
About Zevra Therapeutics, Inc. (ZVRA) — Dividend Analysis 2026
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Compare ZVRA with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ZVRA DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ZVRA position with:
🌍 ZVRA Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ZVRA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 16.13% | 13.33% | $1,613 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 13.71% | 10.91% | $1,371 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 12.90% | 10.10% | $1,290 / yr |
| 🇬🇧 UK ISA | 0% | 16.13% | 13.33% | $1,613 / yr |
| 🇬🇧 UK Taxable | 8.75% | 14.72% | 11.92% | $1,472 / yr |
| 🇨🇦 TFSA | 0% | 16.13% | 13.33% | $1,613 / yr |
| 🇨🇦 CA Taxable | 25% | 12.10% | 9.30% | $1,210 / yr |
| 🇦🇺 Super (pension) | 15% | 13.71% | 10.91% | $1,371 / yr |
| 🇦🇺 AU Taxable | 30% | 11.29% | 8.49% | $1,129 / yr |
| 🇩🇪 DE Taxable | 26.375% | 11.88% | 9.08% | $1,188 / yr |
| 🇫🇷 FR Taxable | 30% | 11.29% | 8.49% | $1,129 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ZVRA Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ZVRA Dividend Payment Schedule
ZVRA pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ZVRA vs Healthcare Benchmarks
How ZVRA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ZVRA sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ZVRA Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-08-14 | 42,666 | $11.13 | $474.8K | ||
| M-Exempt | 2026-08-10 | 12,300 | $4.97 | $61.1K | ||
| M-Exempt | 2026-08-10 | 12,300 | $4.97 | $61.1K | ||
| Sale | 2026-08-10 | 12,300 | $11.25 | $138.4K | ||
| M-Exempt | 2026-06-21 | 66,667 | — | — | ||
| Sale | 2026-06-22 | 34,557 | $12.68 | $438.3K | ||
| M-Exempt | 2026-06-21 | 66,667 | — | — | ||
| A-Award | 2026-06-04 | 30,000 | $11.17 | $335.1K | ||
| A-Award | 2026-06-04 | 30,000 | $11.17 | $335.1K | ||
| A-Award | 2026-06-04 | 30,000 | $11.17 | $335.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ZVRA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Zevra Therapeutics, Inc. (ZVRA) is currently trading at $12.40, 10% below its 52-week high. The current dividend yield is 16.13% based on an annual payout of $2.00 per share.
ZVRA (Zevra Therapeutics, Inc.) — 16.13% Dividend Yield Analysis
Zevra Therapeutics, Inc. (ZVRA) is a healthcare stock currently trading at $12.40 with a dividend yield of 16.13%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (16.13%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ZVRA News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.